Every day in the US, approximately 34 patients are removed from the transplant waiting list either because they die or they become too sick to receive a transplant.
How it Works:
We work with OPOs and transplant surgeons to identify and rescue kidneys that would otherwise be unused.
We keep kidneys alive and healthy with a warm Normothermic preservation, thus extending the time out of body.
We provide a detailed assessment and additional data on each kidney leading to more informed decision making.
The 34 Lives Leadership Team represents a combined 100+ years of experience in the fields of transplantation, healthcare, policy and technology.
CEO Chris Jaynes developed the equipment and technology for ex-vivo or out-of-body lung assessment and is using his background and previous successes to also improve kidney transplantation.
CCO and Co-founder Kathleen St. Jean built a 30-year career at Merck & Co., Inc., with a number of leadership roles in Sales, Professional Learning & Development and Customer Strategy.
“Kathleen and I decided to combine our careers in healthcare and transplantation to help solve the organ transplant crisis in the US. We founded 34 Lives as a Public Benefit Company (PBC) and will not rest until we have forged a new path in ensuring that every donated kidney possible is rescued, revived and transplanted.”
- Chris Jaynes
34 Lives Transforms the Kidney Transplantation Process
What problem are we solving?
In 2022, approximately 115,000 patients in the US were awaiting organ transplants. Of these, 96,000 were waiting for a kidney.
The average wait time for a kidney is 6 years, and during this time most patients will be on dialysis.
In 2022, over 7,800 kidneys were recovered with the intent to be transplanted but were unused.
In 2021, only 18,699 patients (18%) received kidney transplants while 13,292, approximately 34 per day, either died or became too sick to remain on the wait list.
Meet the Team
Chris has spent his 30-year career disrupting services and products in medical device niche markets. He founded 34 Lives in 2021, backed by a Kidney X Award from the US Department of Health & Human Services, the Centers for Medicare & Medicaid, and the National Kidney Foundation.
Kathleen St. Jean
Kathleen’s career in Big Pharma spanned sales, training, and customer strategy, where she was well known for her passion and creativity. After stints at Imedex and SeaStar Medical, she co-founded 34 Lives and is CCO.
Stephen G. Ruby
Dr. Ruby is a Board Certified Anatomic and Clinical Pathologist who leverages over 40 years of laboratory, medical and business experience as the new Lab Director at 34 Lives.
Melissa’s career experiences include overseeing national government programs and policy development for clinical safety in the use of organs, tissues, cells and blood products. She has worked extensively with transplantation and transfusion stakeholder communities.
Stephen is a board certified Transplant Preservationist and certified Ex-Vivo Lung Specialist. Prior to joining 34 Lives, he was the Director of Business Development at MidAmerica Ambulatory Surgery.
For 15+ years, Devon has created financial structures, protocols and procedures for flourishing startups. Devon is an expert in multiple Business Implementation and Financial Software Platforms, specializing in niche biotech startups.
Molly began her career as an advertising copywriter and transitioned to the pharmaceutical industry with Merck where she held a variety of roles over 20 years, including employee communication, promotion, culture and strategy.
We named our company 34 Lives because every day in the US, approximately 34 patients are removed from the transplant waiting list either because they die or they become too sick to receive a transplant.
34 Lives is more than our name: It’s our mission, our passion, our reason for being! We will work tirelessly with other dedicated collaborators and stakeholders to bring the number 34 down to 0.
34 Lives is proud to boast a Leadership Team with a combined 100+ years of experience in the fields of transplantation, healthcare, policy and technology.
CEO Chris Jaynes developed the equipment and technology for ex-vivo or out-of-body lung assessment and is using his background and previous successes to improve kidney transplantation.
Co-founder and CCO Kathleen St. Jean was at Merck & Co., Inc., for 29 years in several leadership roles, including Sales, Professional Learning & Development, customer Strategy and more. In Phase Two of her career, Kathleen worked at Imedex before joining Chris at SeaStar Medical.
Working with a team of seasoned professionals, Chris and Kathleen are committed to honoring each and every organ, each and every donor each and every recipient. The team’s aspiration is to change “Wait Lists” into “Life Lists.”
34 Lives is committed to saving and dramatically improving the lives of the more than 96,000 individuals waiting for lifesaving kidney transplant in the US.
We’re working to develop innovative technology and services that will extend the safe preservation times to rescue the thousands of unused kidneys each year, saving lives that would otherwise be lost on the waitlist.
Keeping a kidney viable for transplant is a race against the clock. In the US, it’s accepted practice to not keep a kidney out of the body for longer than 20 hours to be viable for transplant. We are working to safely double kidney preservation times through our process, thus giving unused kidneys “a second chance” and extra time to make it to a waiting patient.
PBCs are a type of for-profit corporate entity currently authorized by 35 states and the District of Columbia, similar to a C-corp, S-corp, or LLC.
A PBC must prepare an annual benefit report with (1) a description of how the company promoted the public benefits listed in the company’s articles of incorporation and any obstacles the company faced in promoting those public benefits and (2) an assessment of the overall social and environmental performance of the company against a third-party standard.
PBCs must include in their charter one or more specific public benefits as their statement of purpose, which provides for a North Star by which a company can navigate critical business decisions. 34 Lives Statement of Purpose is:
- To save and dramatically improve the lives of critically ill patients as they await organ transplant by providing innovative solutions to rescue donor organ function and improve the chances of a recipient to receive a transplant
We are proud to partner with leading research organizations and universities:
- Purdue Research Foundation, West Lafayette, Indiana, where the 34 Lives team is located
- National Kidney Foundation (NKF), which awarded an Innovation Fund investment to 34 Lives in 2022
34 Lives is currently working on a number of research protocols with organ transplant experts from other countries, including:
- Dr. Anna Krarup Keller, Aarhus University, Denmark
- Professor Henri Leuvenink, University Medical Center Groningen, Netherlands
- Dr. Cyril Moers, University Medical Center Groningen, Netherlands